Enanta Pharmaceuticals, Inc.
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identifyā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.99
Price+1.76%
$0.19
1Y
Price
Market Cap
$234.937m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-84.1%
EBITDA Margin-99.7%
Net Profit Margin+94.7%
Free Cash Flow MarginRevenue
$64.806m
-4.2%
1y CAGR-8.9%
3y CAGR-9.5%
5y CAGREarnings
-$92.012m
+20.7%
1y CAGR+8.0%
3y CAGR-7.5%
5y CAGREPS
-$4.32
+21.2%
1y CAGR+9.1%
3y CAGR-5.9%
5y CAGRBook Value
$79.279m
$301.029m
Assets$221.750m
Liabilities$207.098m
DebtDebt to Assets
68.8%
-2.5x
Debt to EBITDAFree Cash Flow
-$43.572m
+55.0%
1y CAGR+13.2%
3y CAGR+4.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company